Iconic Therapeutics is a biotechnology company focused on developing innovative treatments for serious diseases in the fields of ophthalmology and oncology. Leveraging its deep understanding of tissue factor biology, the company aims to create breakthrough medicines that address inflammation and angiogenesis—key processes involved in disease progression. Iconic Therapeutics serves patients suffering from conditions such as wet age-related macular degeneration (AMD) and various solid tumors. The company operates in the highly competitive biopharmaceutical market and follows a business model that includes research and development, clinical trials, and strategic partnerships. Revenue is generated through licensing agreements, such as those with Zymeworks and Exelixis, and potential future sales of approved therapeutics.

Keywords: biotechnology, ophthalmology, oncology, tissue factor, inflammation, angiogenesis, wet AMD, solid tumors, licensing agreements, clinical trials.